Transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) affects far more patients than most health systems realize — and the data show many are going undiagnosed and unmanaged.1-7
Recent Becker's Healthcare and Alnylam survey research, with perspectives from more than 100 health system leaders, found that only 1 in 3 organizations rated their organizations as very effective at coordinating care across specialties for rare cardiac diseases.
The consequences are measurable. Delayed ATTR-CM diagnosis is associated with a 2x higher in-hospital mortality rate, 17% higher 30-day readmissions and a 46% increase in length of stay.8
In this live webinar, leaders from Advocate Health, University of Chicago Medicine and St. Luke's Health System will share how pharmacy–cardiology collaboration is changing the care delivery model for complex cardiac patients, from patient identification to site of care coordination to the buy-and-bill model.
You will learn:
- How health systems are building programmatic approaches to identifying at-risk patients for rare cardiac diseases
- What cross-specialty coordination models are working — and what the data say about current gaps
- How centralized pharmacy services support benefit verification, prior authorizations and multiple sites of administration
- Opportunities in the buy-and-bill model for provider-administered cardiac medications
